Articles from Caixin Global, Caixin Global

Caixin Global

Caixin is a media group dedicated to providing financial and business news through periodicals, online content, mobile apps, conferences, books and TV/video programs. Caixin aims to blaze a trail that helps traditional media prosper in the new media age through integrated multimedia platforms.

Articles from Caixin Global

News from Caixin

Equity Bottom-Up

Sichuan Biokin Pharmaceutical / Equity Bottom-Up

Sichuan Biokin Pharmaceutical (688506 CH)

<ul><li>Chinese innovative drugmaker <strong>Sichuan Biokin Pharmaceutical Co. Ltd. </strong>has filed with the Hong Kong Stock Exchange for an initial public offering (IPO) in an effort to tap fresh funding to support new drug development and overseas expansion.</li><li>Biokin, already listed in Shanghai, did not disclose the target size of its Hong Kong offering. According to its preliminary prospectus, Goldman Sachs Group Inc., JPMorgan Chase &amp; Co., and Citic Securities Co. Ltd. are joint sponsors for the share sale.</li><li>Founded in 1996, Biokin began as a producer of chemical generic drugs and proprietary Chinese medicines. The company has since 2011 moved on to novel biological drugs, focusing on antibody-drug conjugates (ADCs) for cancer treatment.</li></ul>

Chinese innovative drugmaker Sichuan Biokin Pharmaceutical Co. Ltd. has filed with the Hong Kong Stock Exchange for an initial public offering (IPO) in an effort to tap fresh funding to support new drug development and overseas expansion.Biokin, already listed in Shanghai, did not disclose the target size of its Hong Kong offering. According to its preliminary prospectus, Goldman Sachs Group Inc., JPMorgan Chase &amp; Co., and Citic Securities Co. Ltd. are joint sponsors for the share sale.Founded in 1996, Biokin began as a producer of chemical generic drugs and proprietary Chinese medicines. The company has since 2011 moved on to novel biological drugs, focusing on antibody-drug conjugates (ADCs) for cancer treatment.

Cutting-Edge Drugmaker Biokin Taps Hong Kong Market to Fund Foray Aboard 